Research progress on the correlation between transforming growth factor- β level and symptoms of depression.
10.3724/zdxbyxb-2023-0269
- Author:
Yanran LI
1
;
Huiying WANG
2
;
Jiansong ZHOU
3
;
Changhong WANG
4
Author Information
1. Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical College, Henan Key Laboratory of Biological Psychiatry, Henan Psychological Aid Cloud Platform and Application Engineering Research Center, Xinxiang 453002, Henan Province, China. 3492950269@qq.com.
2. Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical College, Henan Key Laboratory of Biological Psychiatry, Henan Psychological Aid Cloud Platform and Application Engineering Research Center, Xinxiang 453002, Henan Province, China.
3. Department of Psychiatry, the Second Xiangya Hospital of Central South University, National Clinical Medical Research Center for Ment, Changsha 410011, China. zhoujs2003@csu.edu.cn.
4. Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical College, Henan Key Laboratory of Biological Psychiatry, Henan Psychological Aid Cloud Platform and Application Engineering Research Center, Xinxiang 453002, Henan Province, China. wangchdr@163.com.
- Publication Type:Journal Article
- Keywords:
Depression;
Efficacy;
Review;
Target;
Transforming growth factor-β
- MeSH:
Animals;
Mice;
Transforming Growth Factor beta/metabolism*;
Transforming Growth Factor beta1;
Depression;
Cytokines;
Antidepressive Agents/therapeutic use*;
Transforming Growth Factors
- From:
Journal of Zhejiang University. Medical sciences
2023;52(5):646-652
- CountryChina
- Language:English
-
Abstract:
Transforming growth factor (TGF)-β is a group of cytokines with anti-inflammatory effects in the TGF family, which participates in the development of stress and depression-related mechanisms, and plays roles in the regulation of inflammatory response in depression and the recovery of various cytokine imbalances. The core symptoms of depression is associated with TGF-β level, and the psychological symptoms of depression are related to TGF-β gene polymorphism. Various antidepressants may up-regulate TGF-β level through the complex interaction between neurotransmitters and inflammatory factors, inhibiting inflammatory response and regulating cytokine imbalance to improve depressive symptoms. Studies have shown that recombinant TGF-β1 protein has beneficial effects in mouse depression models, indicating TGF-β1 might be a potential therapeutic target for depression and nasal sprays having the advantage of being fast acting delivery method. This article reviews the research progress on dynamic changes of TGF-β level before and after depression treatment and the application of TGF-β level as an indicator for the improvement of depressive symptoms. We provide ideas for the development of new antidepressants and for the evaluation of the treatment efficacy in depression.
